1-3 of 3
Jiajia Feng, MD
Close
Sort by
Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2782.
https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782
Published: 2017
Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2016) 128 (22): 2768.
https://doi.org/10.1182/blood.V128.22.2768.2768
Published: 2016
Journal Articles

Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Greg P. Coffey, PhD, Jiajia Feng, MD, Glenn Michelson, MD, Janet Leads, PhD, John T. Curnutte, MDPhD, Anjali Pandey, PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2015) 126 (23): 3706.
https://doi.org/10.1182/blood.V126.23.3706.3706
Published: 2015